Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA Mutated”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT04296370
What this trial is testing

Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Who this might be right for
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd. 474
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Post-approval studies (Phase 4)Study completedNCT02476968
What this trial is testing

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Who this might be right for
BRCA or HRR+ Mutated Ovarian Cancer Patients
AstraZeneca 181
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Early research (Phase 1)Active Not RecruitingNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Varun Monga, MBBS 13
Large-scale testing (Phase 3)WithdrawnNCT02392676
What this trial is testing

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
AstraZeneca
Testing effectiveness (Phase 2)Ended earlyNCT04377087
What this trial is testing

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sarah E Taylor 3
Testing effectiveness (Phase 2)UnknownNCT04556292
What this trial is testing

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 78
Large-scale testing (Phase 3)Study completedNCT03402841
What this trial is testing

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Who this might be right for
Non-Germline BRCA Mutated Ovarian Cancer
AstraZeneca 279
Not applicableStudy completedNCT04532645
What this trial is testing

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

Who this might be right for
Ovary Cancer
AstraZeneca 342
Not applicableNot Yet RecruitingNCT06393543
What this trial is testing

International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis

Who this might be right for
BRCA MutationSerous Tubal Intraepithelial CarcinomaOvarian Carcinoma+1 more
Radboud University Medical Center 600
Large-scale testing (Phase 3)Looking for participantsNCT06952803
What this trial is testing

Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Who this might be right for
Prostate Cancer
AstraZeneca 700
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Not applicableLooking for participantsNCT03667417
What this trial is testing

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

Who this might be right for
Breast CancersOvarian Cancers
Institut Paoli-Calmettes 5,000
Early research (Phase 1)Study completedNCT01445418
What this trial is testing

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Who this might be right for
Breast CancerOvarian Cancer
National Cancer Institute (NCI) 103
Early research (Phase 1)Ended earlyNCT02358200
What this trial is testing

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Who this might be right for
Triple Negative Metastatic Breast CancerBRCA-mutated Solid Tumor
Pamela Munster 23
Large-scale testing (Phase 3)Study completedNCT03740165
What this trial is testing

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
Merck Sharp & Dohme LLC 1,367
Testing effectiveness (Phase 2)Study completedNCT02889900
What this trial is testing

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Who this might be right for
Recurrent Platinum Resistant Ovarian Cancer
AstraZeneca 62
Very early researchActive Not RecruitingNCT03943173
What this trial is testing

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Who this might be right for
BRCA-Mutated Ovarian CarcinomaBRCA1 Gene MutationBRCA2 Gene Mutation+28 more
M.D. Anderson Cancer Center 15
Early research (Phase 1)Looking for participantsNCT07069335
What this trial is testing

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Boryung Pharmaceutical Co., Ltd 24
Next Page